Physician profile
Brian Robert Sperber
NPI 1356437271
$5,331.26
in general payments reported to CMS, 2019-2025
32 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $149 · 2021: $38.37 · 2022: $114 · 2023: $1,297 · 2024: $1,558 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,888 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,887.68 |
| Education | $239.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,040.64 | 2019-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $565.04 | 2023-2025 | Sotyktu, Sprycel |
| Janssen Biotech, INC. | $516.38 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $469.08 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $421.39 | 2019-2025 | Ilumya, Winlevi |
| Ucb, INC. | $277.91 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $271.50 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $213.33 | 2019-2025 | Dupixent |
| Pfizer INC. | $189.04 | 2022-2025 | |
| Amgen INC. | $185.54 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $176.06 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $137.29 | 2023-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $125.20 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $101.15 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $77.47 | 2025 | Vtama |
| Dermavant Sciences, INC. | $74.01 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $65.81 | 2024-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $43.68 | 2019-2024 | Valchlor |
| Krystal Biotech INC | $39.12 | 2023 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.88 | 2019-2024 | Cabtreo |
| Journey Medical Corporation | $30.93 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.47 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $22.83 | 2025 | |
| Janssen Scientific Affairs, LLC | $21.08 | 2023 | Tremfya |
| Mylan Pharmaceuticals INC. | $20.12 | 2019 | |
| Genentech USA, INC. | $18.36 | 2019 | |
| Mayne Pharma Commercial LLC | $16.34 | 2019 | |
| Botanix Sb INC | $15.71 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $14.75 | 2019 | |
| Hikma Pharmaceuticals USA | $14.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sperber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.